Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.6300
-0.0255 (-3.89%)
At close: Mar 20, 2026
Market Cap204.93M -11.8%
Revenue (ttm)n/a
Net Income-54.17M
EPS-0.25
Shares Out281.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume288,542
Average Volume3,568,498
Open0.6500
Previous Close0.6555
Day's Range0.6210 - 0.6550
52-Week Range0.5515 - 2.4400
Beta0.88
RSI42.38
Earnings DateMay 19, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements